What are the symptoms, diagnostic criteria, and treatment and management strategies for Neuroleptic Malignant Syndrome (NMS), and how should psychotic symptoms be managed after NMS?

Neuroleptic Malignant Syndrome: Symptoms, Diagnosis, Treatment, and Management of Psychotic Symptoms

Immediately discontinue all antipsychotic medications when NMS is suspected, provide aggressive supportive care with IV fluids and cooling measures, and use benzodiazepines as first-line agents for agitation—this approach has reduced mortality from 76% in the 1960s to less than 10-15% currently. 1

Clinical Symptoms

The hallmark tetrad of NMS consists of 1:

• Hyperthermia: Fever up to 41°C or higher
• Altered mental status: Ranges from alert mutism to agitation, stupor, or coma; most commonly presents as delirium
• Muscle rigidity: Lead pipe rigidity is most common, though akinesia, dyskinesia, or waxy flexibility may occur
• Autonomic instability: Tachycardia, blood pressure instability (fluctuations ≥20 mm Hg diastolic or ≥25 mm Hg systolic within 24 hours), diaphoresis, pallor, cardiac dysrhythmias, sialorrhea, dysphagia

Additional motor abnormalities include intermittent tremors, involuntary movements, positive Babinski sign, chorea, seizures, opisthotonos, trismus, and oculogyric crisis 1.

Critical pitfall: Autonomic dysfunction may occur before other symptoms, so early fever with tachycardia in a patient on antipsychotics should raise immediate suspicion 1.

Pathophysiology

NMS results from dopamine D2 receptor blockade in the CNS 1:

• Hypothalamic blockade: Produces elevated temperature set point and loss of heat-dissipating mechanisms
• Nigrostriatal pathway blockade: Causes muscle rigidity and tremor via extrapyramidal pathways
• Peripheral effects: Increased calcium release from sarcoplasmic reticulum leads to increased muscle contractility, rigidity, heat production (worsening hyperthermia), and muscle cell breakdown

Diagnosis

NMS is a clinical diagnosis with no pathognomonic findings 1. The diagnosis requires:

Essential Component

History of antipsychotic use or withdrawal of dopaminergic agent within 3 days 1

Delphi Panel Scoring System 1:

• Exposure to dopamine antagonist or withdrawal of dopamine agonist within 3 days: 20 points
• Hyperthermia (>100.4°F oral on ≥2 occasions): 18 points
• Rigidity: 17 points
• Mental status alteration: 13 points
• Creatine kinase elevation (≥4 times upper limit of normal): 10 points
• Sympathetic nervous system lability: 10 points (defined as ≥2 of: elevated BP ≥25% baseline, BP fluctuations, diaphoresis, or urinary incontinence)
• Hypermetabolism: 5 points (heart rate ≥25% above baseline AND respiratory rate ≥50% above baseline)
• Negative workup for infectious, toxic, metabolic, or neurologic causes: 7 points

Laboratory Findings (Supportive but Not Diagnostic) 1:

• Leukocytosis: 15,000-30,000 cells/mm³
• Elevated creatine kinase (often markedly elevated)
• Elevated alkaline phosphatase, lactic dehydrogenase, transaminases
• Electrolyte abnormalities consistent with dehydration
• Metabolic acidosis

Important caveat: Attenuated or incomplete presentations are possible, making diagnosis challenging 1. A recent study found that the overwhelming majority of cases coded as NMS did not meet DSM-5 diagnostic criteria, emphasizing the need for stricter application of criteria 2.

Risk Factors

High-risk factors include 1:

• Coadministration of psychotropic agents (>50% of NMS cases)
• Dehydration
• Physical exhaustion
• Preexisting organic brain disease
• Long-acting depot antipsychotics
• Young adult males (2:1 male predominance)

Critical point: Neither duration of drug exposure nor toxic overdoses are associated with NMS 1. Reintroducing the original precipitating drug may not cause recurrence, though patients with prior NMS have increased recurrence risk.

Treatment Algorithm

Immediate Actions 1:

1. Discontinue all antipsychotic medications immediately

   • If NMS triggered by abrupt withdrawal of anti-Parkinsonism drug, consider reintroducing that agent

2. Aggressive supportive care:

   • IV fluids for dehydration and rhabdomyolysis
   • External cooling measures (cooling blankets) for hyperthermia
   • Monitor for renal failure; hemodialysis may be necessary (though dialysis does not remove protein-bound antipsychotics)

3. Pharmacologic management:

   • Benzodiazepines as first-line agents for agitation 1
   • Consider bromocriptine (dopamine agonist) 3, 4, 5
   • Consider dantrolene sodium for severe cases 4, 5, 6
   • Anticholinergics should be used judiciously 5

4. Intensive care monitoring:

   • Cardiorespiratory support with standard measures
   • Mechanical ventilation if needed (45% of cases in one series) 2
   • Monitor for complications: rhabdomyolysis, acute kidney injury, metabolic acidosis, seizures, disseminated intravascular coagulopathy

Severe Cases 1:

For temperature >41.1°C, consider emergency sedation, neuromuscular paralysis, and intubation. Avoid physical restraints—they exacerbate isometric contractions, worsening hyperthermia, lactic acidosis, and mortality.

Second-Line Treatment 5:

Electroconvulsive therapy (ECT) may be considered for refractory cases 5, 6.

Management of Psychotic Symptoms After NMS

Waiting Period

Allow adequate recovery time before reintroducing antipsychotics. The evidence does not specify an exact duration, but clinical recovery should be complete.

Reintroduction Strategy 7:

When psychotic symptoms require treatment after NMS recovery:

1. Consider atypical antipsychotics with lower D2 affinity rather than the original precipitating agent
2. Start with lowest effective dose and titrate slowly
3. Avoid high-potency typical antipsychotics (e.g., haloperidol) that were commonly implicated in NMS 2, 3
4. Monitor closely for early signs of recurrence

Important consideration: While haloperidol was the sole inciting agent in 25% of cases in one series, the majority of recent cases involve atypical or second-generation antipsychotics 2, indicating that no antipsychotic is completely safe from causing NMS.

Alternative Approaches:

• For treatment-resistant psychosis after NMS, clozapine may be considered with extreme caution and close monitoring, given its unique efficacy profile 7, 8
• Ensure adequate hydration and avoid other risk factors (physical exhaustion, concomitant psychotropic agents)

Prognosis

Current mortality is <10-15%, down from 76% in the 1960s 1. However, late mortality remains substantial, with 20% dying within 1 month in one recent series (though not directly attributable to NMS) 2. Most patients recover promptly with appropriate treatment 2, 5.